When IATA launched NDC, it was heralded as a way for airlines to create a more tailored experience for passengers. Credit: Andre Babiak/Alamy Stock Photo Distribution specialist APG is seeing a ...

The NDC Members of Parliament, who until Thursday, October 17, 2024, were the Minority Caucus of Parliament of Ghana in the 8th Parliament, are now on the other side of the House—the Majority.

The National Democratic Congress (NDC) has prompted sympathisers to desist from designing and publishing their own adverts for the party's flagbearer, John Dramani Mahama's campaign. In a ...

The Volta Regional Communication Bureau of the National Democratic Congress (NDC) has distributed a total of 200 smartphones to the party’s communicators. According to the Regional Communication ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

The Electoral Commission (EC) of Ghana has applauded the National Democratic Congress (NDC) for recommending the re-exhibition of the Provisional Voters Register ahead of the 2024 general elections.

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data. Arexvy is ...

“We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted Arexvy, indicating our potential best-in-class ...